Beigene, Ltd. ((ONC)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
BeiGene, Ltd. is conducting a Phase 3 clinical study titled A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma. The study aims to compare the efficacy of zanubrutinib plus obinutuzumab against lenalidomide plus rituximab in follicular lymphoma, and zanubrutinib plus rituximab against lenalidomide plus rituximab in marginal zone lymphoma, focusing on progression-free survival.
The interventions being tested include zanubrutinib, obinutuzumab, lenalidomide, and rituximab. Zanubrutinib is an oral medication, while obinutuzumab and rituximab are administered intravenously. Lenalidomide is also taken orally. These treatments are designed to manage relapsed or refractory cases of follicular and marginal zone lymphoma.
The study is interventional with a randomized, parallel assignment model and no masking. Its primary purpose is treatment, aiming to provide effective management options for these lymphomas.
The study began on March 10, 2022, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This study’s results could significantly impact BeiGene’s stock performance and investor sentiment, as positive outcomes may enhance the company’s competitive position in the oncology market. Investors should watch for updates, as these could influence market dynamics and BeiGene’s standing against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.